These awards cover research on a variety of crucial health areas including asthma, heart failure, migraine prevention and more.
The Patient-Centered Outcomes Research Institute (PCORI) has awarded over $150 million in funding for new patient-centered comparative clinical effectiveness research (CER) studies. These initiatives cover a variety of crucial health areas including asthma, heart failure, migraine prevention and more.
Nine awards for patient-centered CER have been granted, with two large-scale trials focusing on heart failure and asthma treatments.
In addition, PCORI awarded funds to enhance CER methodologies and gather evidence on how to improve patient engagement in research.
These investments reflect the growing prevalence of patient-centered research in reshaping clinical approaches, as shared in a report by IQVIA.
Reshaping clinical approaches, according to the report, includes building trust and being open in the relationship between patients and researchers.
When patients are included in every part of the research, from planning to analyzing, it creates a sense of respect on both sides. This not only keeps people engaged but also supplies researchers with crucial data.
Showcasing a wide range of data sources, patient-centered research goes beyond traditional clinical outcomes to include the experiences and preferences of patients, according to the report.
In return, this approach results in the credibility of research findings.
As patient-centered research continues to grow, it marks a significant shift in healthcare toward a model where the patient's perspective supports scientific exploration and ensures that research outcomes benefit who they are meant to.
“As a leading funder of patient-centered comparative clinical effectiveness research, PCORI recognizes the evidence generated from PCORI-funded research helps patients and those who care for them make informed decisions about which health care options will work best for them," PCORI executive sirector Nakela L. Cook, M.D., MPH, said in the release.
Trust, transparency and the utilization of high-quality data is crucial to develop deeper insights and more impactful healthcare solutions.
FDA Updates for Week of April 29, 2024: Full Approval for Tivdak
May 4th 2024The FDA made several approvals this week, including converting Tivdak’s accelerated approval to full approval for cervical cancer and approvals for a high-concentration formulation of Cyltezo, Xolremdi for an ultra rare immune disorder and Libervant Film for epilepsy in young children.
Read More
Older Adults' Concerns Highlight Healthcare Cost and Access Challenges
May 3rd 2024The University of Michigan National Poll on Healthy Aging recently conducted the survey focusing on the concerns of adults aged 50 and above regarding various health-related issues in their communities.
Read More
DC Roundtable: Patrick Cooney of The Federal Group Drops the Latest on PBM Legislation in Washington
April 11th 2024In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Listen